MarketLens
Sign Up

Summit Therapeutics: A High-Stakes Bet on Ivonescimab Amidst a Deepening Cash Crunch

2 months ago
SHARE THIS ON:

Summit Therapeutics: A High-Stakes Bet on Ivonescimab Amidst a Deepening Cash Crunch

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 weeks ago

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

AstraZeneca made a $2B strategic equity investment in Summit Therapeutics and formed a clinical collaboration on ivonescimab and sonesitatug vedotin, advancing Summit's cancer pipeline.
Stock News•1 months ago

November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet

Summit Therapeutics faces a make-or-break FDA PDUFA decision for ivonescimab in NSCLC on November 14, 2026. The drug showed robust PFS and statistically significant OS benefits in Phase III trials. Th...
Stock News•2 months ago

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Summit Therapeutics' partner Akeso received NMPA approval in China on August 12, 2026, for ivonescimab plus chemotherapy as first-line treatment for advanced squamous NSCLC, expanding the drug's marke...

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help